Exagen Raises Annual Revenue Guidance Following Strong Q2 Performance
Key Facts
As healthcare companies prioritize financial sustainability, Exagen has reported strong results that signal a credible path toward profitability. The company delivered 16% revenue growth in the latest quarter, driven by record average selling prices. According to reports, this performance prompted management to raise full-year revenue guidance to a range of $72 million to $75 million.
Financial data revealed that cash generation turned positive during the second quarter, accompanied by an improvement in operating margin to -8.6%. This progress is attributed to operational efficiencies and a tripling of Pharma Services revenue, strengthening the narrative of a turnaround as the company moves closer to EBITDA breakeven.
Looking ahead, investors are focused on the company's ability to maintain record selling prices amid shifting economic conditions.
Latest Updates · 1
- Notable·
Update: Detailed filings show Exagen achieved record quarterly revenue of $19.9 million in Q2 2026. To reach financial sustainability, management has identified an $80 million annual revenue threshold for adjusted EBITDA breakeven, while also signaling growth through the planned launch of a new myositis product in early 2027.